Copeptin and high-sensitive C-reactive protein (hsCRP) are biomarkers associated with increased mortality in patients with cardiovascular and cerebrovascular disease as well as in the general population. No data exist regarding these markers in patients with primary aldosteronism. A total of 113 primary aldosteronism patients (64% male) from two centers of the prospective German Conn’s Registry were identified, for whom a full data set and blood samples at baseline and follow-up (14 ± 3.4 months) after initiation of specific primary aldosteronism treatment were available. These cases were matched 1 : 3 (n = 339) for sex, renal function, BMI, age and SBP with participants from the Cooperative Health Research in the Region of Augsburg F4 survey. Copeptin and hsCRP were determined by sandwich fluoroimmunoassay. Copeptin and hsCRP levels decrease following specific primary aldosteronism therapy reflecting successful cardiovascular risk reduction. However, they are no independent predictors regarding cure of primary aldosteronism.
Authors: Remde Hanna, Dietz Anna, Emeny Rebecca, Riester Anna, Peters Annette, de las Heras Gala Tonia, Then Cornelia, Seissler Jochen, Beuschlein Felix, Reincke Martin, Quinkler, Marcus
Keywords: C-reactive protein, copeptin, aldosteronism treatment outcome
DOI Number: 10.1097/HJH.0000000000001041 Publication Year: 2016
To search for other research papers by topic, keyword, author, or year, please go to our Publications page.